The Pharma Legal Handbook: Norway

Norway is a high-income pharmaceutical market outside the European Union but within the European Economic Area, with a regulatory framework that largely mirrors EU requirements while maintaining national control over key decisions. The Norwegian Medicines Agency (NoMA) manages product authorisation, while the Nye metoder system evaluates new medicines for hospital use.

Norway operates a maximum price system for pharmaceutical products based on the average price in nine reference countries, with separate pricing arrangements for hospital and retail products. The Nye metoder process for hospital medicines is rigorous and can result in significant delays between EMA approval and national availability.

The Pharma Legal Handbook: Norway provides comprehensive guidance on pharmaceutical regulation in Norway, covering NoMA product authorisation, the maximum price system, the Nye metoder evaluation process, clinical trial requirements, pharmacovigilance obligations, manufacturing standards, marketing rules, parallel imports, and intellectual property protection.